Список литературы

Поставить закладку

Navallas M, Inarejos Clemente EJ, Iglesias E, et al. Autoinflammatory diseases in childhood, part 2: polygenic syndromes. Pediatr Radiol 2020;50:431–44. doi:10.1007/s00247-019-04544-9
Денисова Р. В., Алексеева Екатерина Иосифовна, Пинелис В. Г., Баканов М. И., Валиева С. И., Бзарова Т. М., Исаева К. Б., Морев С. Ю., Кузнецова Г. В., Арсеньева Е. Н., Малахов О. А. Эффективность и безопасность ибандроновой кислоты для внутривенного введения при тяжелом системном остеопорозе у больных ювенильным артритом // ВСП. 2011. №6.
Hashkes PJ, Laxer RM, Simon A, editors. Textbook of Autoinflammation. Cham: : Springer International Publishing 2019. doi:10.1007/978-3-319-98605-0
Kuemmerle-Deschner JB. CAPS — pathogenesis, presentation and treatment of an autoinflammatory disease. Semin Immunopathol 2015;37:377–85. doi:10.1007/s00281-015-0491-7
Petty RE, Laxer RM, Lindsley CB, et al. Textbook of pediatric rheumatology. 8th ed. Philadelphia: : Elsevier, Inc 2020.
Efthimiou P, SpringerLink (Online service). Auto-Inflammatory Syndromes Pathophysiology, Diagnosis, and Management. 2019.
Levy R, Gérard L, Kuemmerle-Deschner J, et al. Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry. Ann Rheum Dis 2015;74:2043–9. doi:10.1136/annrheumdis-2013-204991
Federici S, Martini A, Gattorno M. The Central Role of Anti-IL-1 Blockade in the Treatment of Monogenic and Multi-Factorial Autoinflammatory Diseases. Front Immunol 2013;4. doi:10.3389/fimmu.2013.00351
Gattorno M, Hofer M, Federici S, et al. Classification criteria for autoinflammatory recurrent fevers. Ann Rheum Dis 2019;78:1025–32. doi:10.1136/annrheumdis-2019-215048
Federici S, Vanoni F, Ben-Chetrit E, et al. An International Delphi Survey for the Definition of New Classification Criteria for Familial Mediterranean Fever, Mevalonate Kinase Deficiency, TNF Receptor–associated Periodic Fever Syndromes, and Cryopyrin-associated Periodic Syndrome. J Rheumatol 2019;46:429–36. doi:10.3899/jrheum.180056
Kuemmerle-Deschner JB, Ozen S, Tyrrell PN, et al. Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS). Ann Rheum Dis 2017;76:942–7. doi:10.1136/annrheumdis-2016-209686
Terreri MTRA, Bernardo WM, Len CA, et al. Guidelines for the management and treatment of periodic fever syndromes. Rev Bras Reumatol Engl Ed 2016;56:44–51. doi:10.1016/j.rbre.2015.08.020
Kümmerle-Deschner JB, Tyrrell PN, Reess F, et al. Risk factors for severe Muckle-Wells syndrome: MWS Disease Severity Risk Factors. Arthritis Rheum 2010;62:3783–91. doi:10.1002/art.27696
Salugina SO, Fedorov ES, Kuzmina NN. Current approaches to diagnosis, treatment, and monitoring in patients with cryopyrin-associated periodic syndromes (CAPS). Mod Rheumatol J 2016;10:4–11. doi:10.14412/1996-7012-2016-2-4-11.
Кузьмина НН, Салугина СО, Федоров ЕС. Аутовоспалительные заболевания и синдромы у детей. Москва: : ИМА-ПРЕСС 2012.
Hui A, Johnson LB, Greemberg R, et al. Severe cryopyrin-associated periodic syndrome first characterized by early childhood-onset sensorineural hearing loss – Case report and literature review. Int J Pediatr Otorhinolaryngol 2019;120:68–72. doi:10.1016/j.ijporl.2019.01.037
Kilic H, Sahin S, Duman C, et al. Spectrum of the neurologic manifestations in childhood-onset cryopyrin-associated periodic syndrome. Eur J Paediatr Neurol 2019;23:466–72. doi:10.1016/j.ejpn.2019.03.006
Рамеев ВВ, Симонян АХ, Саркисова ИА, et al. Амилоидоз и наследственные периодические аутовоспалительные заболевания. Клиницист 2008;3.https://www.elibrary.ru/item.asp?id=14310188 (accessed 28 May 2021).
Лопаткин НА. Хроническая почечная недостаточность. In: Урология. Москва: : Медицина 1995. 471–85.
Lane T, Loeffler JM, Rowczenio DM, et al. Brief Report: AA Amyloidosis Complicating the Hereditary Periodic Fever Syndromes: AA Amyloidosis and HPFS. Arthritis Rheum 2013;65:1116–21. doi:10.1002/art.37827
Vinceneux P, Pouchot J. De la maladie périodique à l’amylose. Presse Médicale 2005;34:958–66. doi:10.1016/S0755-4982(05)84087-4
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney inter 2013;3:1–150.
ter Haar NM, Oswald M, Jeyaratnam J, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis 2015;74:1636–44. doi:10.1136/annrheumdis-2015-207546
Баранов АА, Алексеева ЕИ, editors. Ревматические болезни у детей. Москва: : ПедиатрЪ 2016.
Рамеев ВВ, Козловская ЛВ, Саркисова ИА. Амилоидоз: вопросы диагностики и лечения. Клиницист 2006;:35–41.
Sag E, Bilginer Y, Ozen S. Autoinflammatory Diseases with Periodic Fevers. Curr Rheumatol Rep 2017;19:41. doi:10.1007/s11926-017-0670-8
Federici S, Gattorno M. A practical approach to the diagnosis of autoinflammatory diseases in childhood. Best Pract Res Clin Rheumatol 2014;28:263–76. doi:10.1016/j.berh.2014.05.005
Davis MDP, van der Hilst JCH. Mimickers of Urticaria: Urticarial Vasculitis and Autoinflammatory Diseases. J Allergy Clin Immunol Pract 2018;6:1162–70. doi:10.1016/j.jaip.2018.05.006
Welzel T, Kuemmerle-Deschner JB. Diagnosis and Management of the Cryopyrin-Associated Periodic Syndromes (CAPS): What Do We Know Today? J Clin Med 2021;10:128. doi:10.3390/jcm10010128
Georgin-Lavialle S, Fayand A, Rodrigues F, et al. Autoinflammatory diseases: State of the art. Presse Médicale 2019;48:e25–48. doi:10.1016/j.lpm.2018.12.003
Hawkins PN, Lachmann HJ, Aganna E, et al. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004;50:607–12. doi:10.1002/art.20033
Li C, Tan X, Zhang J, et al. Gene mutations and clinical phenotypes in 15 Chinese children with cryopyrin-associated periodic syndrome (CAPS). Sci China Life Sci 2017;60:1436–44. doi:10.1007/s11427-017-9246-4
Wittkowski H, Kuemmerle-Deschner JB, Austermann J, et al. MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes. Ann Rheum Dis 2011;70:2075–81. doi:10.1136/ard.2011.152496
Cantarini L, Rigante D, Brizi MG, et al. Clinical and biochemical landmarks in systemic autoinflammatory diseases. Ann Med 2012;44:664–73. doi:10.3109/07853890.2011.598546
Soon GS, Laxer RM. Approach to recurrent fever in childhood. Can Fam Physician Med Fam Can 2017;63:756–62.
Тепаев РФ. Синдром диссеминированного внутрисосудистого свертывания у детей. Диагностика и лечение. Педиатрическая Фармакология 2010;7:27–31.
Ören H, Cingöz I, Duman M, et al. Disseminated intravascular coagulation in pediatric patients: Clinical and Laboratory Features and Prognostic Factors Influencing the Survival. Pediatr Hematol Oncol 2005;22:679–88. doi:10.1080/08880010500278749
Rajagopal R, Thachil J, Monagle P. Disseminated intravascular coagulation in paediatrics. Arch Dis Child 2017;102:187–93. doi:10.1136/archdischild-2016-311053
Rigante D, Leone A, Marrocco R, et al. Long-term response after 6-year treatment with anakinra and onset of focal bone erosion in neonatal-onset multisystem inflammatory disease (NOMID/CINCA). Rheumatol Int 2011;31:1661–4. doi:10.1007/s00296-010-1787-5
Breda, L., Nozzi, M., De Sanctis, S., & Chiarelli, F. (2010). Laboratory Tests in the Diagnosis and Follow-Up of Pediatric Rheumatic Diseases: An Update. Seminars in Arthritis and Rheumatism, 40(1), 53–72. doi:10.1016/j.semarthrit.2008.12.
Kriulin IA, Alexeeva EI, Dvoryakovskaya TM, et al. Cryopyrin-Associated Periodic Syndrome (CAPS) Caused by c.943A>G Variant of NLRP3 Gene: Clinical Case. Curr Pediatr 2019;18:270–6. doi:10.15690/vsp.v18i4.2044
Ben-Chetrit E, Moses AE, Agmon-Levin N, et al. Serum levels of anti-streptolysin O antibodies: their role in evaluating rheumatic diseases: ASO antibodies in evaluating rheumatic diseases. Int J Rheum Dis 2012;15:78–85. doi:10.1111/j.1756-185X.2011.01668.x
Long SS. Distinguishing Among Prolonged, Recurrent, and Periodic Fever Syndromes: Approach of a Pediatric Infectious Diseases Subspecialist. Pediatr Clin North Am 2005;52:811–35. doi:10.1016/j.pcl.2005.02.007
Limper M, de Kruif MD, Duits AJ, et al. The diagnostic role of Procalcitonin and other biomarkers in discriminating infectious from non-infectious fever. J Infect 2010;60:409–16. doi:10.1016/j.jinf.2010.03.016
Howell MD, Davis AM. Management of Sepsis and Septic Shock. 2017;:2.
Weiss SL, Peters MJ, Alhazzani W, et al. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Intensive Care Med 2020;46:10–67. doi:10.1007/s00134-019-05878-6
Жданова, Л. В. Трудности дифференциальной диагностики лихорадок с синдромом сыпи в грудном возрасте / Л. В. Жданова // Медико-фармацевтический журнал Пульс. – 2020. – Т. 22. – № 4. – С. 151-155. – DOI 10.26787/nydha-2686-6838-2020-22-4-151-155.
Щербина АЮ. Первичные иммунодефициты -реалии XXI века. Вопросы Гематологиионкологии И Иммунопатологии В Педиатрии. 2016;15:8-9–9. doi:10.24287/1726-1708-2016-15-1-8-9.
García-Basteiro AL, DiNardo A, Saavedra B, et al. Point of care diagnostics for tuberculosis. Pulmonology 2018;24:73–85. doi:10.1016/j.rppnen.2017.12.002
Аксенова ВА, Барышников ЛА, Клевно НИ, et al. Новые возможности скрининга и диагностики различных проявлений туберкулезной инфекции у детей и подростков в России. Вопросы Современной Педиатрии 2011;10:16–22.
Behringer J, Ryan M, Miller M, et al. Magnetic resonance imaging findings in a patient with cryopyrin-associated periodic syndrome: A rare hereditary multi-system inflammatory disorder. Neuroradiol J 2019;32:420–5. doi:10.1177/1971400919863712
Sood SK. Lyme Disease in Children. Infect Dis Clin North Am 2015;29:281–94. doi:10.1016/j.idc.2015.02.011
Steffen, Hirsch. Diagnostik der Lyme-Borreliose. Ther Umsch 2005;62:737–44. doi:10.1024/0040-5930.62.11.737
Ahmadinejad Z, Mansori S, Ziaee V, et al. Periodic Fever: a review on clinical, management and guideline for Iranian patients - part I. Iran J Pediatr 2014;24:1–13.
McAuley JB. Toxoplasmosis in Children. Pediatr Infect Dis J 2008;27:161–2. doi:10.1097/INF.0b013e3181658abb
Rezaei Z, Pourabbas B, Asaei S, et al. Pediatric visceral leishmaniasis: a retrospective study to propose the diagnostic tests algorithm in southern Iran. Parasitol Res 2021;120:1447–53. doi:10.1007/s00436-021-07067-1
Zanjirani Farahani L, Mohebali M, Akhoundi B, et al. Seroepidemiological study on visceral leishmaniasis in an endemic focus of central Iran during 2017. J Parasit Dis 2019;43:22–7. doi:10.1007/s12639-018-1049-0
Cascio A., Colomba C. Childhood Mediterranean visceral leishmaniasis //Le Infezioni in Medicina. – 2003. – Т. 11. – №. 1. – С. 5-10.
van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010;341:c3369–c3369. doi:10.1136/bmj.c3369
Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis 2014;8:1179–207. doi:10.1016/j.crohns.2014.04.005
Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care—An Evidence-based Guideline From European Crohn’s and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:257–91. doi:10.1097/MPG.0000000000002035
McCrindle BW, Cifra B. The role of echocardiography in Kawasaki disease. Int J Rheum Dis 2018;21:50–5. doi:10.1111/1756-185X.13216
Ziegeler K, Eshed I, Diekhoff T, et al. Imaging of Joints and Bones in Autoinflammation. J Clin Med 2020;9:4074. doi:10.3390/jcm9124074
Houx L, Hachulla E, Kone-Paut I, et al. Musculoskeletal Symptoms in Patients With Cryopyrin-Associated Periodic Syndromes: A Large Database Study: Frequency of joint pain and synovitis IN CAPS. Arthritis Rheumatol 2015;67:3027–36. doi:10.1002/art.39292
Mohd Zaki F, Sridharan R, Sook Pei T, et al. NOMID: The radiographic and MRI features and review of literature. J Radiol Case Rep 2012;6:1–8. doi:10.3941/jrcr.v6i3.745
Alexeeva EI. Juvenile idiopathic arthritis: clinical picture, diagnosis, treatment. Curr Pediatr 2015;14:78–94. doi:10.15690/vsp.v14i1.1266.
Sierra D, Wood M, Kolli S, et al. Pediatric Gastritis, Gastropathy, and Peptic Ulcer Disease. Pediatr Rev 2018;39:542–9. doi:10.1542/pir.2017-0234
Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016). J Pediatr Gastroenterol Nutr 2017;64:991–1003. doi:10.1097/MPG.0000000000001594
Allen-Rhoades W, Whittle SB, Rainusso N. Pediatric Solid Tumors in Children and Adolescents: An Overview. Pediatr Rev 2018;39:444–53. doi:10.1542/pir.2017-0268
Olmedilla G, Undaondo C, Vasquez W, et al. Metastatic Malignant Peritoneal Mesothelioma Mimicking an Autoinflammatory Syndrome in a 12-Year-Old Boy. Pediatr Dev Pathol 2021;24:478–83. doi:10.1177/10935266211008438
Zucker EJ, Lee EY, Restrepo R, et al. Hip Disorders in Children. Am J Roentgenol 2013;201:W776–96. doi:10.2214/AJR.13.10623
Fonseca MB, Gomes FHR, Valera ET, et al. Signs and symptoms of rheumatic diseases as first manifestation of pediatric cancer: diagnosis and prognosis implications. Rev Bras Reumatol Engl Ed 2017;57:330–7. doi:10.1016/j.rbre.2017.01.007
Grebenyuk V. et al. Fever of unknown origin: case reports from routine clinical practice and a review //Klinicka Mikrobiologie a Infekcni Lekarstvi. – 2021. – Т. 27. – №. 4. – С. 148-157.
Castellano A, Falini A. Progress in neuro-imaging of brain tumors. Curr Opin Oncol 2016;28:484–93. doi:10.1097/CCO.0000000000000328
Gupta N, Kaur H, Wajid S. Renal amyloidosis: an update on diagnosis and pathogenesis. Protoplasma 2020;257:1259–76. doi:10.1007/s00709-020-01513-0
Ahmadi N, Brewer CC, Zalewski C, et al. Cryopyrin-Associated Periodic Syndromes: Otolaryngologic and Audiologic Manifestations. Otolaryngol Neck Surg 2011;145:295–302. doi:10.1177/0194599811402296
Oberg TJ, Vitale AT, Hoffman RO, et al. Cryopyrin-associated Periodic Syndromes and the Eye. Ocul Immunol Inflamm 2013;21:306–9. doi:10.3109/09273948.2013.765016
Stucki G, Kroeling P. Physical therapy and rehabilitation in the management of rheumatic disorders. Best Pract Res Clin Rheumatol 2000;14:751–71. doi:10.1053/berh.2000.0111
Luttosch F, Baerwald C. Rehabilitation in der Rheumatologie. Internist 2010;51:1239–45. doi:10.1007/s00108-010-2626-1
Erbis G, Schmidt K, Hansmann S, et al. Living with autoinflammatory diseases: identifying unmet needs of children, adolescents and adults. Pediatr Rheumatol 2018;16:81. doi:10.1186/s12969-018-0300-7
Henderson LA, Cron RQ. Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Childhood Inflammatory Disorders: Diagnosis and Management. Pediatr Drugs 2020;22:29–44. doi:10.1007/s40272-019-00367-1
Ravelli A, Davì S, Minoia F, et al. Macrophage Activation Syndrome. Hematol Oncol Clin North Am 2015;29:927–41. doi:10.1016/j.hoc.2015.06.010
Rigante D, Emmi G, Fastiggi M, et al. Macrophage activation syndrome in the course of monogenic autoinflammatory disorders. Clin Rheumatol 2015;34:1333–9. doi:10.1007/s10067-015-2923-0
Valade S, Mariotte E, Azoulay E. Coagulation Disorders in Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome. Crit Care Clin 2020;36:415–26. doi:10.1016/j.ccc.2019.12.004
Davì S, Minoia F, Cron RQ, et al. Macrophage Activation Syndrome. In: Sawhney S, Aggarwal A, eds. Pediatric Rheumatology. Singapore: : Springer Singapore 2017. 275–92. doi:10.1007/978-981-10-1750-6_22
Yuan W-H, Liu H-C, Zeng L-K, et al. [Change of Thrombelastography in Children’s DIC and Analysis of Its Sensitivity and Specificity for Diagnosis of DIC]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2017;25:847–52. doi:10.7534/j.issn.1009-2137.2017.03.039.
Lehmberg K, Pink I, Eulenburg C, et al. Differentiating Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis from Other Forms of Hemophagocytic Lymphohistiocytosis. J Pediatr 2013;162:1245–51. doi:10.1016/j.jpeds.2012.11.081
Lin C-I, Yu H-H, Lee J-H, et al. Clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases. Clin Rheumatol 2012;31:1223–30. doi:10.1007/s10067-012-1998-0
Cantini F, Nannini C, Niccoli L, et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev 2015;14:503–9. doi:10.1016/j.autrev.2015.01.011
Handa R, Upadhyaya S, Kapoor S, et al. Tuberculosis and biologics in rheumatology: A special situation. Int J Rheum Dis 2017;20:1313–25. doi:10.1111/1756-185X.13129
Vince A, Dusek D. Imunosupresija i virusne infekcije u reumatskim bolestima [Immunosupression and viral infections in rheumatic diseases]. Reumatizam. 2007;54(2):58-62. Croatian. PMID: 18351141.
Gonski K, Cohn R, Widger J, et al. Utility of bronchoscopy in immunocompromised paediatric patients: Systematic review. Paediatr Respir Rev 2020;34:24–34. doi:10.1016/j.prrv.2020.02.003
Eroglu‐Ertugrul NG, Yalcin E, Oguz B, et al. The value of flexible bronchoscopy in pulmonary infections of immunosuppressed children. Clin Respir J 2020;14:78–84. doi:10.1111/crj.13103
Özkoç S, Bayram Deli̇Baş S. Investigation of Pneumocystis jirovecii Pneumonia and Colonization in Iatrogenically Immunosuppressed and Immunocompetent Patients. Mikrobiyol Bul 2015;49:221–30. doi:10.5578/mb.9344
Lachant DJ, Croft DP, McGrane Minton H, et al. The clinical impact of pneumocystis and viral PCR testing on bronchoalveolar lavage in immunosuppressed patients. Respir Med 2018;145:35–40. doi:10.1016/j.rmed.2018.10.021
Ramos JT, Romero CA, Belda S, et al. Clinical practice update of antifungal prophylaxis in immunocompromised children. Rev Espanola Quimioter Publicacion Of Soc Espanola Quimioter 2019;32:410–25.
Tragiannidis A, Kyriakidis I, Zündorf I, et al. Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-α) inhibitors. Mycoses 2017;60:222–9. doi:10.1111/myc.12576
Plosa EJ, Esbenshade JC, Fuller MP, et al. Cytomegalovirus Infection. Pediatr Rev 2012;33:156–63. doi:10.1542/pir.33.4.156
Adler SP, Marshall B. Cytomegalovirus Infections. ;:11.
Vilibic-Cavlek T, Ljubin-Sternak S, Kos L, et al. The role of IgG avidity determination in diagnosis of Epstein-Barr virus infection in immunocompetent and immunocompromised patients. Acta Microbiol Immunol Hung 2011;58:351–7. doi:10.1556/amicr.58.2011.4.10
Nowalk A, Green M. Epstein-Barr Virus. Microbiol Spectr 2016;4:4.3.47. doi:10.1128/microbiolspec.DMIH2-0011-2015
Arduino PG, Porter SR. Herpes Simplex Virus Type 1 infection: overview on relevant clinico-pathological features*: HSV-1 literature review. J Oral Pathol Med 2007;37:107–21. doi:10.1111/j.1600-0714.2007.00586.x
Sharma AP, Norozi K, Filler G, et al. Diagnosis of Pediatric Hypertension: European Society of Hypertension-recommended 24-hr vs. 24-hr-day-night Ambulatory Blood Pressure thresholds. ;:23.
Sandau KE, Funk M, Auerbach A, et al. Update to Practice Standards for Electrocardiographic Monitoring in Hospital Settings: A Scientific Statement From the American Heart Association. Circulation 2017;136. doi:10.1161/CIR.0000000000000527
Scrivo R, Perricone C, Altobelli A, et al. Dietary Habits Bursting into the Complex Pathogenesis of Autoimmune Diseases: The Emerging Role of Salt from Experimental and Clinical Studies. Nutrients 2019;11:1013. doi:10.3390/nu11051013
Minihane AM, Vinoy S, Russell WR, et al. Low-grade inflammation, diet composition and health: current research evidence and its translation. Br J Nutr 2015;114:999–1012. doi:10.1017/S0007114515002093
Sherman JM, Sood SK. Current challenges in the diagnosis and management of fever. Curr Opin Pediatr 2012;24:400–6. doi:10.1097/MOP.0b013e32835333e3
ter Haar NM, Frenkel J. Treatment of hereditary autoinflammatory diseases. Curr Opin Rheumatol 2014;26:252–8. doi:10.1097/BOR.0000000000000059
Levy DM, Imundo LF. Nonsteroidal Anti-Inflammatory Drugs: A survey of practices and concerns of pediatric medical and surgical specialists and a summary of available safety data. Pediatr Rheumatol 2010;8:7. doi:10.1186/1546-0096-8-7
Guillaume-Czitrom S. Les anti-inflammatoires non stéroïdiens dans les rhumatismes inflammatoires chroniques de l’enfant [Non -steroidal anti-inflammatory drugs in chronic inflammatory arthritis in children]. La Lettre du Rhumatologue №379-380 - février-mars 2012.
Litalien C., Jacqz-Aigrain E. Risks and benefits of nonsteroidal anti-inflammatory drugs in children //Paediatric drugs. – 2001. – Т. 3. – №. 11. – С. 817-858.
Hollingworth P. The use of non-steroidal anti-inflammatory drugs in paediatric rheumatic diseases //Rheumatology. – 1993. – Т. 32. – №. 1. – С. 73-77.
Gupta P, Sachdev HP. Safety of oral use of nimesulide in children: systematic review of randomized controlled trials. Indian Pediatr. 2003 Jun;40(6):518-31. PMID: 12824661.
Jiménez Treviño S, Ramos Polo E. Tratamiento de los síndromes periódicos asociados a la criopirina (CAPS). Med Clínica 2011;136:29–33. doi:10.1016/S0025-7753(11)70006-9
Pankow A, Feist E, Baumann U, et al. Was ist gesichert in der Therapie von autoinflammatorischen Fiebererkrankungen? Internist 2021;62:1280–9. doi:10.1007/s00108-021-01220-9
Russo RAG, Melo-Gomes S, Lachmann HJ, et al. Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-centre, real-world experience. Rheumatology 2014;53:665–70. doi:10.1093/rheumatology/ket415
Koné-Paut I, Galeotti C. Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome. Expert Rev Clin Immunol 2015;11:1083–92. doi:10.1586/1744666X.2015.1077702
Brogan PA, Hofer M, Kuemmerle‐Deschner JB, et al. Rapid and Sustained Long‐Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin‐Associated Periodic Syndrome Ages Five Years and Younger. Arthritis Rheumatol 2019;71:1955–63. doi:10.1002/art.41004
Kuemmerle-Deschner JB, Hachulla E, Cartwright R, et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 2011;70:2095–102. doi:10.1136/ard.2011.152728
Imagawa T, Nishikomori R, Takada H, et al. Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results). Clin Exp Rheumatol 2013;31:302–9.
Yokota S, Imagawa T, Nishikomori R, et al. Long-term safety and efficacy of canakinumab in cryopyrin-associated periodic syndrome: results from an open-label, phase III pivotal study in Japanese patients. Clin Exp Rheumatol 2017;35 Suppl 108:19–26.
Kuemmerle-Deschner JB, Gautam R, George AT, et al. A systematic literature review of efficacy, effectiveness and safety of biologic therapies for treatment of familial Mediterranean fever. Rheumatology 2020;59:2711–24. doi:10.1093/rheumatology/keaa205
Piram M, Koné-Paut I, Lachmann HJ, et al. Validation of the Auto-Inflammatory Diseases Activity Index (AIDAI) for hereditary recurrent fever syndromes. Ann Rheum Dis 2014;73:2168–73. doi:10.1136/annrheumdis-2013-203666
ter Haar NM, Annink KV, Al-Mayouf SM, et al. Development of the autoinflammatory disease damage index (ADDI). Ann Rheum Dis 2017;76:821–30. doi:10.1136/annrheumdis-2016-210092
Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol 2016;12:259–68. doi:10.1038/nrrheum.2015.179
Henter J-I. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 2002;100:2367–73. doi:10.1182/blood-2002-01-0172
I.A.Kriulin IAK, Kriulin IA, National Medical Research Center for Children’s Health, Moscow, Russian Federation, et al. Hemophagocytic lymphohistiocytosis: mechanisms of development, clinical manifestations, and treatments. Vopr Prakt Pediatr 2021;16:94–102. doi:10.20953/1817-7646-2021-6-94-102
Bagri NK, Gupta L, Sen ES, et al. Macrophage Activation Syndrome in Children: Diagnosis and Management. Indian Pediatr 2021;58:1155–61. doi:10.1007/s13312-021-2399-8
Stephan J. L. et al. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients //Rheumatology. – 2001. – Т. 40. – №. 11. – С. 1285-1292.
Aizawa-Yashiro T, Oki E, Tsuruga K, et al. Intravenous immunoglobulin therapy leading to dramatic improvement in a patient with systemic juvenile idiopathic arthritis and severe pericarditis resistant to steroid pulse therapy. Rheumatol Int 2012;32:1359–61. doi:10.1007/s00296-010-1413-6
Georgiadou S, Gatselis NK, Stefos A, et al. Efficient management of secondary haemophagocytic lymphohistiocytosis with intravenous steroids and γ-immunoglobulin infusions. World J Clin Cases 2019;7:3394–406. doi:10.12998/wjcc.v7.i21.3394
Roifman CM. Use of intravenous immune globulin in the therapy of children with rheumatological diseases. J Clin Immunol 1995;15:S42–51. doi:10.1007/BF01540893
Sen E. S., Clarke S. L. N., Ramanan A. V. Macrophage activation syndrome //The Indian Journal of Pediatrics. – 2016. – Т. 83. – №. 3. – С. 248-253.
La Rosée P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 2019;133:2465–77. doi:10.1182/blood.2018894618
Chellapandian D, Das R, Zelley K, et al. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. Br J Haematol 2013;162:376–82. doi:10.1111/bjh.12386
Siberry GK, Abzug MJ, Nachman S, et al. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children: Recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. Pediatr Infect Dis J 2013;32:i. doi:10.1097/01.inf.0000437856.09540.11
Green H, Paul M, Vidal L, et al. Prophylaxis of Pneumocystis Pneumonia in Immunocompromised Non-HIV-Infected Patients: Systematic Review and Meta-analysis of Randomized Controlled Trials. Mayo Clin Proc 2007;82:1052–9. doi:10.4065/82.9.1052
Abe Y, Fujibayashi K, Nishizaki Y, et al. Conventional-dose Versus Half-dose Sulfamethoxazole-trimethoprim for the Prophylaxis of Pneumocystis Pneumonia in Patients with Systemic Rheumatic Disease: A Non-blind, Randomized Controlled Trial. 2019. doi:10.18926/AMO/56464
Ghembaza A, Vautier M, Cacoub P, et al. Risk Factors and Prevention of Pneumocystis jirovecii Pneumonia in Patients With Autoimmune and Inflammatory Diseases. Chest 2020;158:2323–32. doi:10.1016/j.chest.2020.05.558
Jiang X, Mei X, Feng D, et al. Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis. PLOS ONE 2015;10:e0122171. doi:10.1371/journal.pone.0122171
Kitazawa T, Seo K, Yoshino Y, et al. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. J Infect Chemother 2019;25:351–4. doi:10.1016/j.jiac.2019.01.005
Park JW, Curtis JR, Kim MJ, et al. Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids—clinical implication of primary prophylaxis using trimethoprim–sulfamethoxazole. Arthritis Res Ther 2019;21:207. doi:10.1186/s13075-019-1996-6
What’s New Adult and Adolescent Opportunistic Infection. AIDSinfo. https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/392/whats-new (accessed 14 Apr 2020).
Henter J-I, Horne A, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48:124–31. doi:10.1002/pbc.21039
Kim BJ, Kim YH, Han JH, Lee SY, Carandang M, Lee DH, Lee S, Choi BY. Outcome of Cochlear Implantation in NLRP3-related Autoinflammatory Inner Ear Disorders. Otol Neurotol. 2021 Feb 1;42(2):e168-e171. doi: 10.1097/MAO.0000000000002933. PMID: 33156237.
Heijstek MW, Ott de Bruin LM, Bijl M, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis 2011;70:1704–12. doi:10.1136/ard.2011.150193
Yilmaz D., Ritchey A. K. Severe neutropenia in children: a single institutional experience //Journal of Pediatric Hematology/Oncology. – 2007. – Т. 29. – №. 8. – С. 513-518.
Алексеева Е., Валиева С., Бзарова Т., Семикина Е., Исаева К., Лисицин А., Денисова Р., Чистякова Е., Слепцова Т., Митенко Е. Эффективность и безопасность отечественного рекомбинантного человеческого гранулоцитарного колониестимулирующего фактора при нейтропениях, развивающихся на фоне анти-в клеточной и иммуносупрессивной терапии у больных ювенильным ревматоидным артритом. Вопросы современной педиатрии. 2010;9(4):94-100.
Dale DC, Crawford J, Klippel Z, et al. A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. Support Care Cancer 2018;26:7–20. doi:10.1007/s00520-017-3854-x
Garcia-Lloret M, McGhee S, Chatila TA. Immunoglobulin Replacement Therapy in Children. Immunol Allergy Clin North Am 2008;28:833–49. doi:10.1016/j.iac.2008.07.001
Захарова И.Н., Османов И.М., Творогова Т.М., Горяйнова А.Н., Дмитриева Ю.А., Воробьева А.С., Короид Н.В. Длительная лихорадка у ребенка: в чем причина, как обследовать, лечить или не лечить? Медицинский совет. 2020;(10):151–162. doi: 10.21518/2079-701X-2020-10-151-162.
El-Nawawy A, El-Kinany H, Hamdy El-Sayed M, et al. Intravenous Polyclonal Immunoglobulin Administration to Sepsis Syndrome Patients: A Prospective Study in a Pediatric Intensive Care Unit. J Trop Pediatr 2005;51:271–8. doi:10.1093/tropej/fmi011
Rao S, Abzug MJ, Carosone-Link P, et al. Intravenous Acyclovir and Renal Dysfunction in Children: A Matched Case Control Study. J Pediatr 2015;166:1462-1468.e4. doi:10.1016/j.jpeds.2015.01.023
Whitley RJ. Herpes simplex virus in children. Curr Treat Options Neurol 2002;4:231–7. doi:10.1007/s11940-002-0040-2
Antiviral Drugs in Children and Adolescents. Pediatr Infect Dis 2020;1:123–8. doi:10.5005/jp-journals-10081-1221
Leuvenink R, Aeschlimann F, Baer W, et al. Clinical course and therapeutic approach to varicella zoster virus infection in children with rheumatic autoimmune diseases under immunosuppression. Pediatr Rheumatol 2016;14:34. doi:10.1186/s12969-016-0095-3
Zhang S, Zhu Y, Jin Y, et al. Difference between Acyclovir and Ganciclovir in the Treatment of Children with Epstein–Barr Virus-Associated Infectious Mononucleosis. Evid Based Complement Alternat Med 2021;2021:1–6. doi:10.1155/2021/8996934
McDiarmid SV, Jordan S, Lee GS, et al. PREVENTION AND PREEMPTIVE THERAPY OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE IN PEDIATRIC LIVER RECIPIENTS1: Transplantation 1998;66:1604–11. doi:10.1097/00007890-199812270-00006
Eisenstein EM, Wolf DG. Cytomegalovirus infection in pediatric rheumatic diseases: a review. Pediatr Rheumatol 2010;8:17. doi:10.1186/1546-0096-8-17
Whyte LA, Al-Araji RA, McLoughlin LM. Guidelines for the management of acute gastroenteritis in children in Europe. Arch Dis Child - Educ Pract Ed 2015;100:308–12. doi:10.1136/archdischild-2014-307253
Bockem�hl J, Roggentin P. Enterale Yersiniosen: Klinische Bedeutung, Epidemiologie, Diagnostik und Pvention. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 2004;47. doi:10.1007/s00103-004-0865-9
Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016). J Pediatr Gastroenterol Nutr 2017;64:991–1003. doi:10.1097/MPG.0000000000001594
Pneumonia in Immunocompromised Patients: Overview, Causes of Pneumonia, HIV/AIDS. Published Online First: 23 March 2020.https://emedicine.medscape.com/article/807846-overview#a11.. (accessed 14 Apr 2020).
Weyant RB, Kabbani D, Doucette K, et al. Pneumocystis jirovecii: a review with a focus on prevention and treatment. Expert Opin Pharmacother 2021;22:1579–92. doi:10.1080/14656566.2021.1915989
Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis: ACR GUIDELINE FOR GLUCOCORTICOID-INDUCED OSTEOPOROSIS PREVENTION AND TREATMENT. Arthritis Rheumatol 2017;69:1521–37. doi:10.1002/art.40137
Galindo-Zavala R, Bou-Torrent R, Magallares-López B, et al. Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children. Pediatr Rheumatol 2020;18:20. doi:10.1186/s12969-020-0411-9
Zhang Y, Milojevic D. Protecting Bone Health in Pediatric Rheumatic Diseases: Pharmacological Considerations. Pediatr Drugs 2017;19:193–211. doi:10.1007/s40272-017-0219-3
Kutilek S, Plasilova I, Langer J. Ibandronate in the treatment of pediatric osteoporosis. Bone Abstr Published Online First: 9 June 2015. doi:10.1530/boneabs.4.P80
Conklin AI, Hong J. Obesity prevention in corticosteroid‐treated patients: Use and effectiveness of strategies for weight management. Clin Obes 2019;9. doi:10.1111/cob.12312
Kazem Y, Zarouk WA, Hamed K, et al. The Effect of Anti-inflammatory Diet and Vitamin D Supplementation on the Amelioration of the Clinical Status and Cognitive functions of Familial Mediterranean Fever Patients. Kobe J Med Sci 2021;66:E159–65.
Hansmann S, Lainka E, Horneff G, et al. Consensus protocols for the diagnosis and management of the hereditary autoinflammatory syndromes CAPS, TRAPS and MKD/HIDS: a German PRO-KIND initiative. Pediatr Rheumatol 2020;18:17. doi:10.1186/s12969-020-0409-3
Piram M, Frenkel J, Gattorno M, et al. A preliminary score for the assessment of disease activity in hereditary recurrent fevers: results from the AIDAI (Auto-Inflammatory Diseases Activity Index) Consensus Conference. Ann Rheum Dis 2011;70:309–14. doi:10.1136/ard.2010.132613
Koç R, Sönmez HE, Çakan M, et al. Drug reactions in children with rheumatic diseases receiving parenteral therapies: 9 years’ experience of a tertiary pediatric rheumatology center. Rheumatol Int 2020;40:771–6. doi:10.1007/s00296-019-04498-z
Puxeddu I, Giori L, Rocchi V, et al. Hypersensitivity reactions during treatment with infliximab, etanercept, and adalimumab. Ann Allergy Asthma Immunol 2012;108:123–4. doi:10.1016/j.anai.2011.11.004
Mulders-Manders CM, Kanters TA, van Daele PLA, et al. Decreased quality of life and societal impact of cryopyrin-associated periodic syndrome treated with canakinumab: a questionnaire based cohort study. Orphanet J Rare Dis 2018;13:59. doi:10.1186/s13023-018-0799-1
Kuemmerle-Deschner JB, Hofer F, Endres T, et al. Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome. Rheumatology 2016;55:689–96. doi:10.1093/rheumatology/kev416
Marsaud C, Marie I, Koné-Paut I. Longterm Followup of Quality of Life in Patients with Cryopyrin-associated Periodic Syndrome Treated with Canakinumab, an Anti-interleukin 1β Monoclonal Antibody. J Rheumatol 2014;41:1721–2. doi:10.3899/jrheum.131291